Polyrizon Ltd. (PLRZ) News
Track canonical SquawkNews coverage tagged to PLRZ, Polyrizon Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Polyrizon completes fourth and fifth U.S. site contracts for NASARIX allergy study
Polyrizon said it has completed contracting for the fourth and fifth U.S. clinical sites for NASARIX™ first-in-human allergy study, completing all five U.S. site contracts for the trial.
GEOPOLITICS | Sep 02, 2026, 11:37 AM UTC
M
Polyrizon completes all five U.S. site contracts for NASARIX allergy study
Polyrizon (PLRZ) has completed all five U.S. site contracts for its NASARIX first-in-human allergy study.
EQUITY | Sep 02, 2026, 11:32 AM UTC
L
Polyrizon completes clinical site network for NASARIX study
Polyrizon says it has completed the clinical site network for its NASARIX study and is advancing toward patient enrollment, with no catalyst or timing details supplied.
EQUITY | Aug 20, 2026, 01:30 PM UTC
H
Polyrizon Reports NASARIX Biocompatibility Results, Supporting Advancement To First-In-Human Clinical Trial
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ )
EARNINGS | Jul 02, 2026, 08:13 PM UTC